BioTech
Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial
SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens of approvals, extending the lives of patients, and bringing in
Jonathan Wosen and Adam Feuerstein
September 8, 2024